AOD-9604 for fat loss: what the evidence actually shows

What did @leleomonteiro actually say?

Honestly, the transcript here is a mess. The auto-generated captions appear to be a garbled machine translation of Portuguese audio, producing phrases like "sandwich making and scents" and "parachute that is not possible" that have no coherent meaning. The actual substantive claim lives in the written caption, not the spoken words: AOD-9604 "is not approved for human use and is still in the laboratory testing phase." That is the claim worth checking.

Because the transcript itself is unusable for direct quotation, this fact-check will focus on the caption claim and the broader context around AOD-9604, which is the peptide the creator is clearly discussing given the post category and hashtags targeting the bodybuilding community.

Does the science back this up?

Mostly yes, but the framing is slightly outdated. AOD-9604 is a modified fragment of human growth hormone (hGH), specifically amino acids 176-191, designed to stimulate fat breakdown without the insulin-desensitizing effects of full hGH. It has not been approved by the FDA, EMA, or TGA for any human therapeutic indication. The creator's core claim holds up.

The clinical history is more nuanced than "still in lab testing," though. AOD-9604 actually completed Phase IIb and Phase III human clinical trials for obesity treatment, run by Metabolic Pharmaceuticals in the early 2000s. The trials failed to meet primary endpoints for weight loss (Heffernan et al., 2001, Growth Hormone and IGF Research). The compound was not abandoned because it was dangerous, it was abandoned because it did not work well enough for obesity at the doses tested. That is a meaningful distinction the caption glosses over.

What did they get wrong (or right)?

The creator deserves credit for telling their 17,700 viewers not to use this peptide. That is a responsible position in a space flooded with bodybuilding influencers who promote unregulated peptides without any caveats.

Where they fall short is precision. Saying AOD-9604 is "still in laboratory testing" implies it has never been studied in humans. It has. The compound reached Phase III trials before development was discontinued. Calling it a preclinical-only substance misrepresents where it actually sits in the research timeline. The accurate statement is that it completed clinical trials, failed to achieve approval, and has no current regulatory pathway for human use in any major jurisdiction.

There is also a well-documented gray market reality the caption ignores. AOD-9604 is widely sold through research chemical suppliers and compounding pharmacies in some countries. Bodybuilders are injecting it right now. Acknowledging that while still warning against use would have been more honest and more useful to the audience.

What should you actually know?

If you are considering AOD-9604 because you read that it burns fat without affecting blood sugar, here is what the actual data looks like. Animal studies did show fat-reduction effects (Ng et al., 2000, Journal of Endocrinology). Human trials did not replicate these results at clinically meaningful levels. The mechanism sounds compelling on paper. The human evidence does not support using it.

The safety profile is also not well characterized for the doses circulating in bodybuilding communities. No regulatory body has signed off on a safe human dose because no application has been approved. Compounded or research-grade AOD-9604 has no guaranteed purity, potency, or sterility standards equivalent to a pharmaceutical product.

• AOD-9604 has no FDA, EMA, or TGA approval for any human use.
• It failed Phase III obesity trials and development was discontinued.
• Research-grade peptides sold online carry contamination and mislabeling risks.
• The fat-loss mechanism observed in rodents has not translated reliably to humans in controlled trials.

Bottom line

The creator's warning is directionally correct. AOD-9604 should not be used for bodybuilding or fat loss. The caption would be stronger if it accurately reflected that this peptide reached human trials and failed, rather than implying it has never left the lab. In a content category where misinformation runs in the other direction, getting the basic "do not use this" message right matters more than the imprecise framing around it.